This website is intended only for US healthcare professionals; if you are not a US healthcare professional, please visit www.BioMarin.com

Hemophilia A

Learn more about Hemophilia A and BioMarin therapies

Hemophilia A Clinical Program

Learn about Hemophilia A clinical trials and research at BioMarin.

Educational Materials

Plain Language Summaries

  • Plain Language Summaries
  • Hemophilia A

BioMarin develops these in an effort to increase visibility, impact, and transparency of our scientific research.

A synopsis of a scientific publication written so a non-specialist audience can understand.

View content

Website

  • Educational Materials
  • Hemophilia A

Hemophilia Independent Medical Education

Access Hemophilia Independent Medical Education

View content

Plain Language Summaries

  • Plain Language Summaries
  • Hemophilia A

Outcomes for men with severe hemophilia A 3 years after treatment with valoctocogene roxaparvovec gene therapy

A synopsis of a scientific publication written so a non-specialist audience can understand.

View content

Plain Language Summaries

  • Plain Language Summaries
  • Hemophilia A

Outcomes for men with severe hemophilia A 2 years after treatment with valoctocogene roxaparvovec gene therapy

A synopsis of a scientific publication written so a non-specialist audience can understand.

View content

Tools

  • Educational Materials
  • Hemophilia A

Clinical Trial Tool

Get information on clinical studies for valoctocogene roxaparvovec using the BMN 270 Clinical Program Tool

View content

Video

  • Educational Materials
  • Hemophilia A

Gene Therapy Mechanism of Action

Watch now

Website

  • Educational Materials
  • Hemophilia A

Gene Therapy Research

Learn more about and access educational materials for gene therapy research.

View content

Hemophilia A Congress Posters and Presentations

Access posters and presentations from recent congresses

BioMarin’s enduring commitment to communicate safety information on valoctocogene roxaparvovec